Dewberry Engineers Inc. v. Dewberry Group, Inc.

Track this case

Case Number:

22-1622

Court:

Appellate - 4th Circuit

Nature of Suit:

3840 Trademark

  1. July 21, 2025

    How GOP Judges Teed Up 4th Circ.'s Supreme Court Shutout

    No appeals court found the U.S. Supreme Court's latest term less endearing than the Fourth Circuit, where a supersize shutout accentuated a multiyear slump for the once-favored circuit and repeatedly vindicated conservative dissenters on the left-leaning bench.

  2. September 19, 2023

    Full 4th Circ. Refuses To Reconsider $48M Decision In IP Row

    The full Fourth Circuit on Tuesday declined to revisit a split panel's recent decision backing a Virginia federal court order finding that an Atlanta hotel and real estate developer owes an engineering firm $48 million for using the same name, rejecting the developer's petition for a rehearing en banc.

  3. August 09, 2023

    4th Circ. Affirms Developer Owes $48M In 'Dewberry' TM Row

    The Fourth Circuit decided Wednesday that a federal judge had it right when he ordered an Atlanta hotel and real estate developer to pay an engineering firm $48 million for using the same name — over the protests of a dissenting judge who argued that "it should be for the jury, not a judge, to decide whether the trademark is likely to create confusion."

  4. May 03, 2023

    'Y'all Do Different Stuff,' Judge Says In $48M Trademark Feud

    A judge on a Fourth Circuit panel on Wednesday had some tough questions for an engineering firm that won almost $48 million in a trademark feud with an Atlanta hotel and real estate developer that shares the same name, saying in a hearing that it was "at least debatable" the companies were competitors since "y'all do different stuff."

  5. April 27, 2023

    IP Forecast: Gov't To Face Off Against Gilead In Delaware

    In one of its first-ever patent infringement cases against a private company, the federal government next week will argue before a Delaware jury that Gilead is making billions of dollars in sales from HIV treatments that allegedly violate government-owned patents. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.